Buntinx A - Search Results

1

Dose-dependent kinetics of the enantiomers of MK-571, and LTD4-receptor antagonist.

Depré M, Margolskee DJ, Van Hecken A, Hsieh JS, Buntinx A, De Schepper PJ, Rogers JD. Depré M, et al. Among authors: buntinx a. Eur J Clin Pharmacol. 1992;43(4):431-3. doi: 10.1007/BF02220622. Eur J Clin Pharmacol. 1992. PMID: 1451726 Clinical Trial.

2

Pharmacodynamics and tolerability of L-654,066, a steroid 5 alpha-reductase inhibitor, in men.

Depré M, Meeter C, Van Hecken A, Laskin OL, Buntinx A, De Schepper PJ. Depré M, et al. Among authors: buntinx a. Clin Pharmacol Ther. 1992 Oct;52(4):409-12. doi: 10.1038/clpt.1992.163. Clin Pharmacol Ther. 1992. PMID: 1424413 Clinical Trial.

3

Plasma drug profiles and tolerability of MK-571 (L-660,711), a leukotriene D4 receptor antagonist, in man.

Depré M, Margolskee DJ, Hsieh JY, Van Hecken A, Buntinx A, De Lepeleire I, Rogers JD, De Schepper PJ. Depré M, et al. Among authors: buntinx a. Eur J Clin Pharmacol. 1992;43(4):427-30. doi: 10.1007/BF02220621. Eur J Clin Pharmacol. 1992. PMID: 1451725 Clinical Trial.

4

MK-571, a potent antagonist of leukotriene D4-induced bronchoconstriction in the human.

Kips JC, Joos GF, De Lepeleire I, Margolskee DJ, Buntinx A, Pauwels RA, Van der Straeten ME. Kips JC, et al. Among authors: buntinx a. Am Rev Respir Dis. 1991 Sep;144(3 Pt 1):617-21. doi: 10.1164/ajrccm/144.3_Pt_1.617. Am Rev Respir Dis. 1991. PMID: 1892302 Clinical Trial.

5

Lack of interaction between famotidine and warfarin.

De Lepeleire I, Van Hecken A, Verbesselt R, Tjandra-Maga TB, Buntinx A, Distlerath L, De Schepper PJ. De Lepeleire I, et al. Among authors: buntinx a. Int J Clin Pharmacol Res. 1990;10(3):167-71. Int J Clin Pharmacol Res. 1990. PMID: 2228341

6

Biochemical activity, pharmacokinetics, and tolerability of MK-886, a leukotriene biosynthesis inhibitor, in humans.

Depre M, Friedman B, Tanaka W, Van Hecken A, Buntinx A, DeSchepper PJ. Depre M, et al. Among authors: buntinx a. Clin Pharmacol Ther. 1993 May;53(5):602-7. doi: 10.1038/clpt.1993.76. Clin Pharmacol Ther. 1993. PMID: 8387904 Clinical Trial.

7

Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers.

Van Hecken A, Schwartz JI, Depré M, De Lepeleire I, Dallob A, Tanaka W, Wynants K, Buntinx A, Arnout J, Wong PH, Ebel DL, Gertz BJ, De Schepper PJ. Van Hecken A, et al. Among authors: buntinx a. J Clin Pharmacol. 2000 Oct;40(10):1109-20. J Clin Pharmacol. 2000. PMID: 11028250 Clinical Trial.

8

Hormonal effects, tolerability, and preliminary kinetics in men of MK-906, a 5 alpha-reductase inhibitor.

De Schepper PJ, Imperato-McGinley J, Van Hecken A, De Lepeleire I, Buntinx A, Carlin J, Gressi MH, Stoner E. De Schepper PJ, et al. Among authors: buntinx a. Steroids. 1991 Sep;56(9):469-71. doi: 10.1016/0039-128x(91)90003-e. Steroids. 1991. PMID: 1666698

9

Hormonal effects of a 5 alpha-reductase inhibitor (finasteride) on hormonal levels in normal men and in patients with benign prostatic hyperplasia.

Vermeulen A, Giagulli VA, De Schepper P, Buntinx A. Vermeulen A, et al. Among authors: buntinx a. Eur Urol. 1991;20 Suppl 1:82-6. doi: 10.1159/000471752. Eur Urol. 1991. PMID: 1722168 Clinical Trial.

10

Hormonal effects of an orally active 4-azasteroid inhibitor of 5 alpha-reductase in humans.

Vermeulen A, Giagulli VA, De Schepper P, Buntinx A, Stoner E. Vermeulen A, et al. Among authors: buntinx a. Prostate. 1989;14(1):45-53. doi: 10.1002/pros.2990140106. Prostate. 1989. PMID: 2538808

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

22 results

Search Page

Filters